Amit Gupta Sells 6,785 Shares of Cardlytics (NASDAQ:CDLX) Stock

Posted by Brian Himes on Aug 20th, 2026

Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) CEO Amit Gupta sold 6,785 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $3.97, for a total transaction of $26,936.45. Following the completion of the sale, the chief executive officer directly owned 132,065 shares in the company, valued at approximately $524,298.05. This represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Amit Gupta also recently made the following trade(s):

On Tuesday, August 18th, Amit Gupta sold 6,676 shares of Cardlytics stock. The stock was sold at an average price of $4.03, for a total transaction of $26,904.28.
On Monday, July 6th, Amit Gupta sold 9,640 shares of Cardlytics stock. The stock was sold at an average price of $4.39, for a total transaction of $42,319.60.
On Thursday, July 2nd, Amit Gupta sold 6,498 shares of Cardlytics stock. The shares were sold at an average price of $4.39, for a total transaction of $28,526.22.

Cardlytics Trading Up 3.4%

Shares of CDLX opened at $4.26 on Thursday. The firm’s fifty day simple moving average is $4.35 and its two-hundred day simple moving average is $6.95. Cardlytics, Inc. has a 12 month low of $3.49 and a 12 month high of $32.80. The stock has a market capitalization of $24.75 million, a P/E ratio of -0.23 and a beta of 0.62.

Cardlytics (NASDAQ:CDLX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($2.30) by $0.80. The firm had revenue of $36.88 million during the quarter, compared to analyst estimates of $37.00 million. Cardlytics had a negative return on equity of 956.56% and a negative net margin of 55.92%. As a group, research analysts predict that Cardlytics, Inc. will post -3.89 EPS for the current fiscal year.

Institutional Trading of Cardlytics

A number of hedge funds and other institutional investors have recently bought and sold shares of CDLX. Two Sigma Investments LP lifted its stake in shares of Cardlytics by 44.7% in the third quarter. Two Sigma Investments LP now owns 125,938 shares of the company’s stock valued at $306,000 after buying an additional 38,900 shares in the last quarter. Jane Street Group LLC increased its position in shares of Cardlytics by 263.0% during the second quarter. Jane Street Group LLC now owns 162,427 shares of the company’s stock worth $267,000 after acquiring an additional 117,687 shares in the last quarter. Bridgeway Capital Management LLC increased its position in shares of Cardlytics by 96.2% during the third quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $248,000 after acquiring an additional 50,000 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Cardlytics by 143.5% in the 2nd quarter. XTX Topco Ltd now owns 85,971 shares of the company’s stock worth $141,000 after acquiring an additional 50,663 shares during the last quarter. Finally, Voleon Capital Management LP acquired a new stake in shares of Cardlytics in the 3rd quarter worth about $127,000. Institutional investors own 68.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research note on Thursday, June 18th. Lake Street Capital set a $10.00 price target on Cardlytics in a research note on Friday, May 8th. Wall Street Zen upgraded Cardlytics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cardlytics in a report on Wednesday, July 8th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Sell” and a consensus price target of $10.00.

Read Our Latest Research Report on Cardlytics

About Cardlytics

(Get Free Report)

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.